1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Renhe Pharmacy Co., Ltd. Class A

Renhe Pharmacy Co., Ltd. Class A

SSZSE:000650
5.09
CNY
+0.05
(+0.99%)
8.04BMarket Cap
Oct 27Next Earn
Renhe Pharmacy Co., Ltd. Class A
SZSE:000650
(Shenzhen Stock Exchange)

Recent

price

5.09

P/E

ratio

- -

div

yld

0.01%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.73
1.97
1.7
1.48
1.8
2.06
2.87
3.13
3.56
3.66
3.39
3.56
3.68
3.64
2.96
2.52
- -
Revenue per Share
0.28
0.27
0.21
0.16
0.24
0.32
0.3
0.31
0.41
0.43
0.46
0.48
0.41
0.41
0.35
0.28
- -
Basic EPS, GAAP
0.13
0.05
-0.05
0.1
0.18
0.29
0.37
0.37
0.4
0.44
0.53
0.2
0.75
0.23
0.2
0.55
- -
Free Cash Flow per Basic Share
0.11
0.02
0.03
0.01
0.08
0.02
- -
0.1
0.1
0.1
0.13
0.2
0.1
0.2
0.2
0.15
- -
Dividend per Share
0.74
0.99
1.31
1.47
1.64
1.93
2.22
2.43
2.74
3.07
3.64
3.78
4.1
4.28
4.41
4.51
4.61
Book Value per Share
0.52
0.76
0.89
1.05
1.24
1.52
1.32
1.55
1.9
2.45
3.09
2.88
3.26
3.58
3.82
4.02
4.12
Tangible Book Value per Share
792
1,191
1,228
1,214
1,254
1,223
1,241
1,227
1,235
1,251
1,261
1,385
1,401
1,384
1,377
1,404
1,390
Basic Weighted Avg Shares
1,367
2,341
2,088
1,799
2,253
2,524
3,567
3,844
4,403
4,581
4,278
4,936
5,153
5,032
4,075
3,536
- -
Sales/Revenue/Turnover
21
17.41
14.64
14.53
17.66
21.27
15.03
14.03
17.25
17.68
18.83
19.06
18.18
20.37
20.04
20.27
- -
Operating Margin (%)
27
36
56
64
69
74
80
87
92
88
82
87
117
142
123
116
- -
Depreciation Expense
220
324
255
194
301
391
372
380
506
538
580
665
574
567
482
393
- -
Net Income, GAAP
22.07
19.55
19.97
21.87
23.32
23.88
22.92
22.69
22.67
24.83
22.39
22.67
25.38
29.98
26.86
26.66
- -
Effective Tax Rate (%)
16.06
13.84
12.24
10.79
13.35
15.5
10.44
9.89
11.5
11.74
13.56
13.47
11.15
11.27
11.83
11.12
- -
Profit Margin (%)
488
686
760
898
1,009
1,219
1,358
1,701
2,214
2,697
3,171
3,087
3,416
3,833
4,183
4,182
4,375
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
4
6
- -
2
1
1
LT Debt
912
1,262
1,712
1,939
2,162
2,601
3,204
3,472
3,915
4,352
5,639
5,927
6,422
6,655
6,806
6,932
7,110
Total Equity
23.44
28.23
15.87
10.88
15
17
13.92
12.67
15.12
14.44
13.23
13.33
11.03
9.26
8.25
7.03
- -
Return on Invested Capital (%)
23.23
25.94
15.73
9.44
13.56
14.38
10.82
9.58
11.62
11.04
9.69
9.12
7.08
7.72
5.9
4.35
- -
Return on Capital (%)
24.81
31.72
18.32
11.27
15.59
17.7
14.49
13.2
15.83
14.95
13.04
12.81
10.42
9.67
7.92
6.3
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,384
1,400
1,400
Market Capitalization
8,348
7,910
8,036

Working Capital

CNY

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
4,944
5,159
Cash, Cash Equivalents & STI
- -
3,867
3,989
Accounts Receivable, Net
- -
207
513
Inventories
- -
531
389
Total Current Liabilities
- -
763
785
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.62%
4.24%
1.85%
Free Cash Flow
39.05%
64.36%
186.04%
Net Income, GAAP
1.08%
-6.74%
-18.41%
Sales/Revenue/Turnover
4.63%
-2.96%
-13.21%
Total Cash Common Dividend
20,960.78%
18.25%
-24.81%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,238
1,127
786
924
4,075
2025
986
989
- -
703
3,536
2026
1,129
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.12
0.06
0.05
0.35
2025
0.12
0.09
- -
0.01
0.28
2026
0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.2
2025
- -
- -
- -
- -
0.15
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Renhe Pharmacy Co., Ltd. is a Chinese pharmaceutical company founded in 1996 and headquartered in Nanchang, Jiangxi Province. The company specializes in the research, development, production, and sale of a broad range of pharmaceutical products, including traditional Chinese medicines and Western medicines. Its core product portfolio encompasses oral solid and liquid preparations, large-volume injections, small-volume injections, external lotions, liniments, suppositories, ointments, and bulk drug APIs, alongside various health-related products. Renhe Pharmacy operates predominantly in China, serving diverse customer segments through a comprehensive distribution network that includes smart pharmacies. Recently, the company has enhanced its retail pharmacy network in major Chinese cities such as Beijing, Shanghai, Shenzhen, and Foshan, focusing on smart pharmacies qualified for online national medical insurance purchases. This digitalization and regional optimization strategy aligns with its efforts to expand service density and market scale, improve product quality and operational efficiency, and strengthen supply chain logistics in North, Central, and South China. In terms of latest developments, Renhe Pharmacy has pursued strategic moves including the renewal of key product procurement agreements with partners and intensified investment in its digital pharmacy ecosystem aimed at integrating treatment, diagnosis, pharmaceutical products, and medical insurance services. The company reported a total operating income of approximately CNY 4.075 billion in 2024, with a net profit attributable to shareholders of CNY 482 million, marking a year-on-year decrease, and declared a cash dividend for shareholders. It continues to enhance its merchandise and sales capabilities while consolidating its leading market position through a focus on tailored digitalization at individual stores and centralized procurement of branded products. Renhe Pharmacy is recognized within the pharmaceutical industry for its production of both OTC drugs and prescription medicines, producing popular products such as Compound Paracetamol and Amantadine Hydrochloride Capsules for common cold treatment, Miconazole Nitrate Cream for skin diseases, and pediatric formulations for influenza prevention and treatment. The company has accrued various corporate honors, reflecting its market presence and commitment to quality and innovation.